ArriVent BioPharma develops cancer medicines, led by firmonertinib for certain types of lung cancer. AVBP reports earnings on Mon, Nov 16, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 27 | Guggenheim | Target raised | Buy | |
| Oct 20 | B. Riley Securities | Maintained | Buy | |
| Oct 8 | HC Wainwright & Co. | Target lowered | Buy | |
| Oct 7 | Citigroup | Target lowered | Buy | |
| Oct 7 | Jones Trading | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in AVBP in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AVBP is in one of them and how their past AVBP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AVBP in an article yet. Here's the latest on the wider market.
About ArriVent BioPharma
ArriVent BioPharma is a clinical stage biopharmaceutical company based in Newtown Square, Pennsylvania. It develops cancer treatments for patients, with its lead candidate, firmonertinib, aimed at non-small cell lung cancer linked to certain EGFR gene mutations. The company is also developing antibody drug conjugates, including ARR 217, for solid tumors. Its candidates are still in clinical trials and have not been approved by the U.S. Food and Drug Administration.
- Headquarters
- Newtown Square, PA